NASDAQ · ORKA
Oruka Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ORKA: Nov 11, 2026
Oruka Therapeutics, Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.68. The reported EPS for the same quarter last year was $-0.55.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.68 | $-0.57 | $-0.87 | 5 |
| Dec 2026 | $-0.67 | $-0.59 | $-0.75 | 5 |
| Mar 2027 | $-0.66 | $-0.60 | $-0.70 | 3 |
| Jun 2027 | $-0.68 | $-0.61 | $-0.75 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
MarketBeat · RTTNews · The Motley Fool · Zacks- MarketBeat · Oct 26, 11:02 PM EDTOruka’s ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis StudyOruka Therapeutics (NASDAQ:ORKA) reported interim week 16 results from EVERLAST-B, a Phase IIb dose-ranging study of ORKA-001 in adults with moderate-to-severe plaque psoriasis. The company said its 600-milligram regimen achieved complete skin clearance, measured by PASI 100, in
- RTTNews · Oct 26, 3:25 PM EDTThree Movers And A Catalyst: SGRY, XNCR, ORKA Gain As Acumen Nears ALTITUDE-AD Readout(RTTNews) – Shares of several biotech companies moved sharply higher following corporate and clinical developments. Surgery Partners surged on reports of a late-stage buyout talks with Bon Secours Mercy Health, Xencor rallied on updated Phase 1 data for XmAb819 in kidney cancer,
- RTTNews · Oct 26, 9:36 AM EDTOruka's Experimental Drug Shows Strong Skin Clearance In Phase 2 Psoriasis Trial(RTTNews) – Oruka Therapeutics (ORKA) reported positive Phase 2b results showing that its experimental drug ORKA-001 demonstrated high rates of skin clearance in patients with moderate-to-severe plaque psoriasis, according to data from the EVERLAST-B study.
- RTTNews · Oct 26, 9:16 AM EDTOruka Advances ORKA-001 Toward Phase 3 After Positive Psoriasis Data(RTTNews) – Oruka Therapeutics (ORKA) reported positive Week 16 Phase 2b EVERLAST-B results for ORKA-001 in moderate-to-severe psoriasis.
- The Motley Fool · Oct 15, 3:34 PM EDTThese 2 Stocks Have Run Circles Around the Magnificent Seven This Year, and Wall Street Says There Is More Upside AheadRevolution Medicines recently made a breakthrough in oncology.
- RTTNews · Sep 25, 10:53 AM EDTWeekly Buzz: MESO, LLY, ANIP Win FDA Nod; KALA, HCTI Sign LOI; IMVT Halts Lupus Study(RTTNews) – Biotech and pharma companies delivered a busy slate of updates, spanning regulatory approvals, multibillion-dollar drug discovery partnerships and pivotal clinical-trial readouts across oncology, metabolic diseases, immunology and rare diseases.
- Zacks · Sep 24, 9:35 AM EDTORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy DataOruka's ORKA-001 delivers deeper psoriasis clearance at week 28, but safety disclosures may have weighed on shares despite positive efficacy data.
- RTTNews · Sep 23, 8:07 AM EDTOruka Reports Positive Week 28 Results For ORKA-001 In Plaque Psoriasis; Stock Down(RTTNews) – Oruka Therapeutics, Inc. (ORKA) announced positive Week 28 results from its ongoing Phase 2a EVERLAST-A trial evaluating ORKA-001 in patients with moderate-to-severe plaque psoriasis.
- Zacks · Aug 28, 11:10 AM EDTORKA Stock Up More Than 60% in 3 Months: Here's What You Should KnowOruka's three-month rally reflects investor confidence in ORKA-001, with key clinical data and pipeline milestones scheduled ahead.
- BNK Invest · Aug 25, 10:54 AM EDTXBI, TWST, ORKA, APGE: Large Inflows Detected at ETFLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $316.0 million dollar inflow — that's a 2.8% increase week over week in
- RTTNews · Aug 24, 10:01 PM EDTOruka Appoints Todd Edwards As CCO Ahead Of ORKA-001 & ORK-002 Commercialization(RTTNews) – Oruka Therapeutics, Inc. (ORKA), a clinical-stage biotechnology company developing biologics for chronic skin diseases, announced on Monday the appointment of Todd Edwards as Chief Commercial Officer (CCO), effective August 24, 2026.
- RTTNews · Aug 21, 7:20 AM EDTShow Me The Money: ORKA Makes A Splash With A 500%+ Gain; More Catalysts Ahead(RTTNews) – Oruka Therapeutics Inc. (ORKA) has been one of biotech's standout performers, with its shares steadily advancing on encouraging clinical data from its pipeline of drug candidates.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Oruka Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.